Cencora
About: Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Employees: 46,000
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
73% more first-time investments, than exits
New positions opened: 154 | Existing positions closed: 89
30% more call options, than puts
Call options by funds: $1.2B | Put options by funds: $924M
26% more repeat investments, than reductions
Existing positions increased: 466 | Existing positions reduced: 369
1% more funds holding
Funds holding: 1,143 [Q3] → 1,155 (+12) [Q4]
0.95% more ownership
Funds ownership: 99.39% [Q3] → 100.35% (+0.95%) [Q4]
2% less capital invested
Capital invested by funds: $44.1B [Q3] → $43.3B (-$737M) [Q4]
27% less funds holding in top 10
Funds holding in top 10: 15 [Q3] → 11 (-4) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$251
4%
upside
Avg. target
$277
15%
upside
High target
$301
25%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
Evercore ISI Group John Belton 50% 1-year accuracy 2 / 4 met price target | 16%upside $280 | Outperform Maintained | 6 Feb 2025 |
Wells Fargo Eric Luebchow 60% 1-year accuracy 29 / 48 met price target | 4%upside $251 | Equal-Weight Maintained | 29 Jan 2025 |
JP Morgan Lisa Gill 57% 1-year accuracy 13 / 23 met price target | 25%upside $301 | Overweight Maintained | 24 Jan 2025 |
Financial journalist opinion
Based on 23 articles about COR published over the past 30 days
Positive
Zacks Investment Research
21 hours ago
Why Cencora (COR) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Positive
Zacks Investment Research
1 day ago
Here's Why Cencora (COR) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Positive
Zacks Investment Research
1 week ago
3 GARP Stocks That Investors Can Scoop Up for Maximum Returns
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. AXP, COR and TPX hold promise.
Neutral
Business Wire
2 weeks ago
Cencora Announces Common Share Repurchase From Walgreens Boots Alliance
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $50 million in concurrence with Walgreens Boots Alliance's sale of Cencora shares pursuant to Rule 144 under the Securities Act of 1933, as amended. Cencora intends to repurchase shares from Walgreens Boots Alliance at the price per share equal to the price in the Rule 144 sale. The con.
Neutral
Business Wire
2 weeks ago
Walgreens Boots Alliance Early-Settles Certain Prepaid Variable Share Forward Transactions and Sells Related Shares of Cencora For Approximately $300 Million of Proceeds
DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) has agreed to the early settlement of certain prepaid variable share forward transactions it had previously entered into with various financial institutions, with respect to shares of Cencora, Inc. (NYSE: COR). Under these transactions, the Company had previously received cash payments in an aggregate amount of approximately $1.1 billion on or about the dates of first entering into them. The transactions were schedul.
Neutral
Business Wire
2 weeks ago
Cencora Reinforces Efforts to Strengthen Pharmaceutical Supply Chain with Expansion of Drug Shortages Mitigation Program
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global healthcare company, has significantly expanded the number and type of medications available in its sure supply program, a drug shortage mitigation initiative designed to provide health systems with reliable access to critical medications, including those at risk of going on shortage. Nearly 200 medications – including several oncology treatments – are now available through the program, which represents an increase of more than 350% since the.
Positive
Zacks Investment Research
2 weeks ago
COR Stock Gains on Q1 Earnings & Revenue Beat & Upbeat '25 Outlook
COR's first-quarter fiscal 2025 results showcase a strong segmental performance. The company's sales and earnings guidance for fiscal 2025 looks encouraging.
Neutral
Seeking Alpha
2 weeks ago
Cencora (COR) Q1 2025 Earnings Call Transcript
Cencora Inc. (NYSE:COR ) Q1 2025 Earnings Conference Call February 5, 2025 8:30 AM ET Company Participants Robert Mauch - President, Chief Executive Officer James Cleary - Executive Vice President, Chief Financial Officer Bennett Murphy - Senior Vice President, Head of Investor Relations Conference Call Participants Michael Cherny - Leerink Partners Lisa Gill - JP Morgan Elizabeth Anderson - Evercore ISI Steven Valiquette - Mizuho Securities Eric Percher - Nephron Research Daniel Grosslight - Citi Stephen Baxter - Wells Fargo Charles Rhyee - TD Cowen Allen Lutz - Bank of America George Hill - Deutsche Bank Erin Wright - Morgan Stanley Kevin Caliendo - UBS Eric Coldwell - Baird Operator Hello and welcome everyone to the Cencora Q1 fiscal year 2025 earnings call. My name is Becky and I'll be your Operator today.
Positive
Zacks Investment Research
2 weeks ago
Here's What Key Metrics Tell Us About Cencora (COR) Q1 Earnings
The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Positive
Zacks Investment Research
2 weeks ago
Cencora (COR) Surpasses Q1 Earnings and Revenue Estimates
Cencora (COR) came out with quarterly earnings of $3.73 per share, beating the Zacks Consensus Estimate of $3.50 per share. This compares to earnings of $3.28 per share a year ago.
Charts implemented using Lightweight Charts™